Robert Gluckman, MD, MACP, from Providence Health Plan, discusses what he was most interested in hearing about at our Institute for Value-Based Medicine® event held in Newport Beach, California, on November 2.
Robert Gluckman, MD, MACP, chief medical officer, Providence Health Plan, spoke with The American Journal of Managed Care® about topics he was looking forward to hearing about at our recent Institute for Value-Based Medicine (IVBM) evening held in partnership with Providence Health System, in Newport Beach, California.
Gluckman was a discussant on the evening's final panel, "Applying Cost and Evidence to Pharmacy Coverage Policy and Benefits."
Transcript
What were you most interested in hearing about at our Newport Beach IVBM?
One of the things I was really interested in hearing about is how an acute care organization like Providence is really dealing with formulary issues and how to bring the most value to patients, while also controlling costs. Its hospitals really are challenged by by high health care costs today.
What were you most excited about speaking on in the final group panel?
I think that what I'm really trying to convey in this session is that there are a number of things that plans, providers, and patients face when trying to address how to get the most benefit from pharmaceuticals. The process is kind of murky and messy for people. So I really want to talk about the pressure points between payer [and] provider and see how we can reduce those so that patients can get the care that they need.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discuss innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
LLMs Show Promise, But Challenges Remain in Improving Inefficient Clinical Trial Screening
July 31st 2025Large language models (LLMs) such as GPT-3.5 and GPT-4 may offer a solution to the costly and inefficient process of manual clinical trial screening, which is often hindered by the inability of structured electronic health record data to capture all necessary criteria.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More